Latest Expert Exchange Queries
sitemapHome | Registration | Job Portal for CA's | Expert Exchange | Currency Converter | Post Matrimonial Ads | Post Property Ads
 
 
News shortcuts: From the Courts | News Headlines | VAT (Value Added Tax) | Service Tax | Sales Tax | Placements & Empanelment | Various Acts & Rules | Latest Circulars | New Forms | Forex | Auditing | Direct Tax | Customs and Excise | ICAI | Corporate Law | Markets | Students | General | Indirect Tax | Mergers and Acquisitions | Continuing Prof. Edu. | Budget Extravaganza | Transfer Pricing
 
 
 
 
Popular Search: VAT RATES :: ACCOUNTING STANDARD :: due date for vat payment :: ARTICLES ON INPUT TAX CREDIT IN VAT :: VAT Audit :: empanelment :: ICAI offer Get Windows 7,Office 2010 in Rs.799 Taxes :: articles on VAT and GST in India :: ACCOUNTING STANDARDS :: Central Excise rule to resale the machines to a new company :: cpt :: list of goods taxed at 4% :: TAX RATES - GOODS TAXABLE @ 4% :: form 3cd :: TDS
 
 
Mergers and Acquisitions »
 New Indirect Tax Regime: Homebuyers and renters keeping fingers crossed on GST impact
 Hitachi India appoints Bharat Kaushal as managing director
 RBI issues new draft rules for M&As
 The 12 digital health mergers and acquisitions of Q1 2017
  Deals of the day-Mergers and acquisitions Apr 19, 2017
 Deals of the day-Mergers and acquisitions Apr 19, 2017
 Foreign investors giving M&A deals in India’s renewable energy sector a miss
 Mergers and acquisitions are getting riskier as insurance claims rise
 The Financial Times started a mergers and acquisitions newsletter for its highest-paying subscribers
 Milton Barbarosh Offering Assistance on Mergers & Acquisitions
 Deals of the day-Mergers and acquisitions 15 April 2017

M&A deals to expand market presence
July, 15th 2009

Lifeline Industries Ltd engaged in the manufacture of active pharmaceutical ingredients (APIs) and intermediates is aggressively scouting for promising mergers and acquisitions (M&A) as part of its inorganic growth strategy. It is now looking at units which can fit into its line of business both in India and abroad.

Viewing opportunities in the market, the company under its organic growth efforts has also invested $50 million and is currently in the process of modernizing units at Bidar in north Karnataka, Solapur and Tarapur in Maharashtra to generate more capacities and also seek US FDA certification for its Mahad plant.

Since Lifeline has made substantial investments in the last couple of years, it is now focused on a fast paced growth plan. M&As are done to synergize and increase scale of operation. Efforts are on to tap Africa, CIS, Latin America, Russia, Brazil which have good opportunity for growth. "We are gearing up for growth both through organic and inorganic paths. This is through constant expansion of capacities to offer new products besides scout for potential M&A deals", Nikunj Kanakia, chairman & managing director, Lifeline Industries told Pharmabiz.

The company will go ahead with its aggressive growth strategy this fiscal, despite the economic slowdown. There have been positive and negative fallouts of the global slow down. On the positive side, most pharma and healthcare companies are looking at low cost destinations to manufacture their products. India still remains an attractive destination for most pharma companies globally. Due to recession, the country is the most preferred market for setting up operations. On the negative side, payment cycles have gone up leading to liquidity issues for quite a few companies. But the economic slow down has given Lifeline an opportunity to focus more on its operational efficiencies, he added.

Prospects of API and intermediates' are powered by the growth in generics and demand from regulated market for outsourcing. The demand is expected to grow at CAGR of 15-18 per cent with market size between $13billion and $15 billion.

As far as growth opportunities in India are concerned, focus will be on generics market. The recent trends are drugs going off patent and rise in Contract Research and Manufacturing Services (CRAMS) due to cost advantage.

In the last decade, the market has gone through a sea of change and India is today the third largest API manufacturer in the world with the highest number of US FDA approved plants.

Now there is a reverse trend as India has emerged as an important global player from being a mere importer of API. Today, the number of Drug Master Files filed by companies here are on the rise. This change is attributed to the core competency of Indian players giving importance to R&D and upgrading the plants to international standards. This will see India's API sales in overseas markets expected to be grow higher than domestic sales.

 
 
Home | About Us | Terms and Conditions | Contact Us
Copyright 2017 CAinINDIA All Right Reserved.
Designed and Developed by Binarysoft Technologies Pvt. Ltd.
Binarysoft Technologies - Contact Us

Transfer Pricing | International Taxation | Business Consulting | Corporate Compliance and Consulting | Assurance and Risk Advisory | Indirect Taxes | Direct Taxes | Transaction Advisory | Regular Compliance and Reporting | Tax Assessments | International Taxation Advisory | Capital Structuring | Withholding tax advisory | Expatriate Tax Reporting | Litigation | Badges | Club Badges | Seals | Military Insignias | Emblems | Family Crest | Software Development India | Software Development Company | SEO Company | Web Application Development | MLM Software | MLM Solutions